• by bcarlson@marketresearch.com
  • May 6 2014
  • vaccine
  • flu

Vaccine Revenues Near 24 Billion

Vaccine Revenues Near 24 Billion

In 2013, the world market for preventive vaccines totaled $23.9 billion, up from $22.8 billion in 2012 as sales in all segments expanded, according to our latest report.    Among some the growth leaders was influenza vaccines, where greater awareness, new products and overstock recovery lead to 3.1 billion in revenues,  up from 2.8 billion in 2012.

                The influenza increase is significant according to Kalorama because there had been a large decrease in the influenza vaccine market in 2011.  Vaccines sales in that year dropped 30%.  Now Kalorama sees double-digit revenue growth for the remainder of the decade.

“We are back to 2008 market levels,” said Bruce Carlson, Publisher of Kalorama information.  “Sales in this segment had been excessively strong, over six billion dollars in 2010 due to government stockpiling - and perhaps over-purchasing - of avian and swine flu.  The market paid for that last two years, but it’s at normal levels now. ”

New Products are part of the reason for the increase, according to Kalorama’s report.  Until 2013, seasonal influenza vaccines included only one B strain.  Now quadravalents were added to product mixes; approximately 20% of doses in the US had two B strains.

A stronger early flu season and increased awarness of the dangers of influenza helped boost sales, according to Kalorama.  Vaccination can prevent about 50% of deaths from pneumococcal disease and 80% of deaths from influenza-related complications in the elderly. Pharmacoeconomic studies have demonstrated the value of influenza and pneumococcal vaccines; however, despite various vaccination campaigns and promotional efforts, immunization rates for these diseases continue to be low in the elderly population.   In the U.S., for example, the Centers for Disease Control (CDC) has found that Influenza is responsible for 20,000 to 40,000 deaths annually, and up to 50,000 deaths and an estimated 200,000 excess hospitalizations at a cost of $750 million to $1 billion during epidemic years.   Kalorama believes awareness of these costs on a personal and institutional level have driven sales to normal levels.

The report covers other categories of vaccines and makes forecasts about the future.  Kalorama Information’s new report, Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments The report can be found at: http://www.marketresearch.com/Kalorama-Information-v767/Vaccines-Key-Players-Trends-Pediatric-8120410/